Gene Signatures of Estrogen and Progesterone Receptor Pathways Predict the Prognosis of Colorectal Cancer

Case ID:
Disclosure Date:
1. Currently adjuvant chemotherapy in CRC is universally recommended for stage III but still controversial in stage II. Conventional clinical and pathologic risk factors are insufficient to identify patients with stage II CRC who carry a high recurrent risk and require adjuvant therapy. This study demonstrated that the gene signature of ER pathway was able to well predict the recurrent risk of stage II CRC patient, suggesting the potential application of this signature as a novel marker to help refine risk assessment for patients with early-stage CRC. 2. The gene signatures of ER and PR pathway could be used to identify patients with stage III CRC who would benefit from adjuvant chemotherapy.
Patent Information:
For Information, Contact:
Nakisha Holder
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum